How much did ImmunoGen achieve in EBIT for the current year?
In the current year, ImmunoGen has achieved an EBIT of 277.81 M USD.
ImmunoGen EBIT 2025
ImmunoGen EBIT
277.81 M USD
Ticker
IMGN
ISIN
US45253H1014
WKN
878613
In 2025, ImmunoGen's EBIT was 277.81 M USD, a 138.01% increase from the 116.72 M USD EBIT recorded in the previous year.
The ImmunoGen EBIT history
| YEAR | EBIT (M USD) |
|---|---|
| 2030e | - |
| 2029e | 700.5 |
| 2028e | 734.1 |
| 2027e | 615.47 |
| 2026e | 466.61 |
| 2025e | 277.81 |
| 2024e | 116.72 |
| 2023e | 15.27 |
| 2022 | -220.9 |
| 2021 | -125.1 |
| 2020 | -20.9 |
| 2019 | -70.8 |
| 2018 | -157.7 |
| 2017 | -58.2 |
| 2016 | -125 |
| 2015 | -54.5 |
| 2014 | -71.5 |
| 2013 | -73 |
| 2012 | -73.3 |
| 2011 | -60.2 |
| 2010 | -51.2 |
| 2009 | -31.8 |
| 2008 | -34.1 |
| 2007 | -22.2 |
| 2006 | -21.4 |
| 2005 | -12.7 |
| 2004 | -8.4 |
| 2003 | -24.6 |
ImmunoGen Revenue, EBIT, Net Income
3 years
5 years
10 years
25 Years
Max
Loading chart...
Revenue
EBIT
Net Income
Details
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into ImmunoGen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ImmunoGen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ImmunoGen’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of ImmunoGen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into ImmunoGen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing ImmunoGen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ImmunoGen’s growth potential.
ImmunoGen Revenue, EBIT and net profit per share
| Date | ImmunoGen Revenue | ImmunoGen EBIT | ImmunoGen Net Income |
|---|---|---|---|
| 2030e | 1.41 B undefined | 0 undefined | 538.04 M undefined |
| 2029e | 1.3 B undefined | 700.5 M undefined | 499.24 M undefined |
| 2028e | 1.32 B undefined | 734.1 M undefined | 540.62 M undefined |
| 2027e | 1.22 B undefined | 615.47 M undefined | 481.98 M undefined |
| 2026e | 1.03 B undefined | 466.61 M undefined | 366.2 M undefined |
| 2025e | 794.2 M undefined | 277.81 M undefined | 222.03 M undefined |
| 2024e | 560.86 M undefined | 116.72 M undefined | 97.19 M undefined |
| 2023e | 384.16 M undefined | 15.27 M undefined | 19.58 M undefined |
| 2022 | 108.8 M undefined | -220.9 M undefined | -222.9 M undefined |
| 2021 | 69.9 M undefined | -125.1 M undefined | -139.3 M undefined |
| 2020 | 132.3 M undefined | -20.9 M undefined | -44.4 M undefined |
| 2019 | 82.3 M undefined | -70.8 M undefined | -104.1 M undefined |
| 2018 | 53.4 M undefined | -157.7 M undefined | -168.8 M undefined |
| 2017 | 115.4 M undefined | -58.2 M undefined | -96 M undefined |
| 2016 | 60 M undefined | -125 M undefined | -144.8 M undefined |
| 2015 | 85.5 M undefined | -54.5 M undefined | -60.7 M undefined |
| 2014 | 59.9 M undefined | -71.5 M undefined | -71.4 M undefined |
| 2013 | 35.5 M undefined | -73 M undefined | -72.8 M undefined |
| 2012 | 16.4 M undefined | -73.3 M undefined | -73.3 M undefined |
| 2011 | 19.3 M undefined | -60.2 M undefined | -58.3 M undefined |
| 2010 | 13.9 M undefined | -51.2 M undefined | -50.9 M undefined |
| 2009 | 28 M undefined | -31.8 M undefined | -31.9 M undefined |
| 2008 | 40.2 M undefined | -34.1 M undefined | -32 M undefined |
| 2007 | 38.2 M undefined | -22.2 M undefined | -19 M undefined |
| 2006 | 32.1 M undefined | -21.4 M undefined | -17.8 M undefined |
| 2005 | 35.7 M undefined | -12.7 M undefined | -11 M undefined |
| 2004 | 26 M undefined | -8.4 M undefined | -5.9 M undefined |
| 2003 | 7.6 M undefined | -24.6 M undefined | -20 M undefined |
ImmunoGen stock margins
The ImmunoGen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImmunoGen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImmunoGen.
3 years
5 years
10 years
25 Years
Max
Loading chart...
Gross margin
EBIT margin
Profit margin
Details
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the ImmunoGen's sales revenue. A higher gross margin percentage indicates that the ImmunoGen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the ImmunoGen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the ImmunoGen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ImmunoGen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ImmunoGen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ImmunoGen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
ImmunoGen Margin History
| ImmunoGen Gross margin | ImmunoGen Profit margin | ImmunoGen EBIT margin | ImmunoGen Profit margin |
|---|---|---|---|
| 2030e | 99.82 % | 0 % | 38.16 % |
| 2029e | 99.82 % | 53.8 % | 38.34 % |
| 2028e | 99.82 % | 55.57 % | 40.93 % |
| 2027e | 99.82 % | 50.45 % | 39.51 % |
| 2026e | 99.82 % | 45.39 % | 35.62 % |
| 2025e | 99.82 % | 34.98 % | 27.96 % |
| 2024e | 99.82 % | 20.81 % | 17.33 % |
| 2023e | 99.82 % | 3.98 % | 5.1 % |
| 2022 | 99.82 % | -203.03 % | -204.87 % |
| 2021 | 99.82 % | -178.97 % | -199.28 % |
| 2020 | 99.82 % | -15.8 % | -33.56 % |
| 2019 | 99.82 % | -86.03 % | -126.49 % |
| 2018 | 99.82 % | -295.32 % | -316.1 % |
| 2017 | 99.82 % | -50.43 % | -83.19 % |
| 2016 | 99.82 % | -208.33 % | -241.33 % |
| 2015 | 99.82 % | -63.74 % | -70.99 % |
| 2014 | 99.82 % | -119.37 % | -119.2 % |
| 2013 | 99.82 % | -205.63 % | -205.07 % |
| 2012 | 99.82 % | -446.95 % | -446.95 % |
| 2011 | 99.82 % | -311.92 % | -302.07 % |
| 2010 | 99.82 % | -368.35 % | -366.19 % |
| 2009 | 99.82 % | -113.57 % | -113.93 % |
| 2008 | 99.82 % | -84.83 % | -79.6 % |
| 2007 | 99.82 % | -58.12 % | -49.74 % |
| 2006 | 91.59 % | -66.67 % | -55.45 % |
| 2005 | 74.23 % | -35.57 % | -30.81 % |
| 2004 | 78.08 % | -32.31 % | -22.69 % |
| 2003 | 63.16 % | -323.68 % | -263.16 % |
ImmunoGen Aktienanalyse
What does ImmunoGen do?
ImmunoGen Inc is a leading company in the biotechnology industry. The company was founded in 1981 as a research facility. In recent decades, ImmunoGen Inc has specialized in the development of antibody-drug conjugates (ADCs). ADCs are drugs that consist of an antibody and a cytotoxin that specifically targets tumor cells. In this way, cancer cells can be selectively destroyed without damaging surrounding tissue. ImmunoGen Inc has achieved success in recent years, particularly in the development of ADCs against serious cancers such as lung cancer or breast cancer, and it also collaborates with major pharmaceutical companies such as Roche or Bayer. The business model of ImmunoGen Inc, therefore, consists of developing innovative cancer drugs and successfully bringing them to market. Another branch of the company is the development of therapeutics for other diseases such as rheumatoid arthritis or multiple sclerosis. ImmunoGen Inc also utilizes ADCs to selectively destroy disease-specific cells in these cases. In the past, ImmunoGen Inc has successfully launched several products on the market. For example, in 2019, the cancer drug Kadcyla, manufactured by Roche and based on ImmunoGen's ADC technology, was approved by the US Food and Drug Administration (FDA) for the treatment of certain types of breast cancer. The ADC development candidate IMGN632 also shows promising results in the treatment of acute myeloid leukemia and other cancer diseases. The history of ImmunoGen Inc has also been marked by some challenges. In the early years of the company, it faced financial difficulties and sold a large number of shares to an investor in 1999. However, the company remained diligent in research and development and eventually became one of the leading biotech companies in the field of cancer research with the development of ADCs. Nevertheless, the company has also experienced setbacks in the development of products and has had to discontinue several development programs. Despite everything, ImmunoGen Inc is considered a successful company in the biotechnology industry, effectively marketing its innovative solutions in the oncology market. It is also being closely watched to see whether future ADCs will not have to undergo as long development cycles as their predecessors, which can guarantee long-term success for the company. ImmunoGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing ImmunoGen's EBIT
ImmunoGen's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of ImmunoGen's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
ImmunoGen's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in ImmunoGen’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about ImmunoGen stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company ImmunoGen.
How has the EBIT of ImmunoGen developed in recent years?
The EBIT of ImmunoGen has increased by 138.014% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company ImmunoGen?
The EBIT of ImmunoGen is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does ImmunoGen pay?
Over the past 12 months, ImmunoGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmunoGen is expected to pay a dividend of 0 USD.
What is the dividend yield of ImmunoGen?
The current dividend yield of ImmunoGen is .
When does ImmunoGen pay dividends?
ImmunoGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmunoGen?
ImmunoGen paid dividends every year for the past 0 years.
What is the dividend of ImmunoGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmunoGen located?
ImmunoGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmunoGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmunoGen from 10/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2025.
When did ImmunoGen pay the last dividend?
The last dividend was paid out on 10/7/2025.
What was the dividend of ImmunoGen in the year 2024?
In the year 2024, ImmunoGen distributed 0 USD as dividends.
In which currency does ImmunoGen pay out the dividend?
The dividends of ImmunoGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmunoGen
Our stock analysis for ImmunoGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmunoGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
